Skip to main content
. 2019 Dec;31(6):974–983. doi: 10.21147/j.issn.1000-9604.2019.06.13

3.

Results of health economic evaluation

Screening group Cost-effectiveness (RMB/LYS) Cost-utility (RMB/QALY) Cost-benefit
LBC, liquid-based cytology; HPV, human papillomavirus; LYS, life year saved; QALY, quality-adjusted life year.
LBC
 Every 3 years 51,421.13 14,633.30 5.00
HPV
 Every 3 years 59,191.55 15,425.69 4.70
 Every 5 years 44,971.21 12,174.41 6.21
HPV+LBC
 Every 3 years 79,252.94 22,417.89 3.42
 Every 5 years 64,250.21 18,709.44 4.28